An interventional study of Nasal 180° Selective Laser Trabeculoplasty (SLT) and Inferior 180° Selective Laser Trabeculoplasty (SLT) in Open Angle Glaucoma, sponsored by Mayo Clinic. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment
The purpose of this study to optimize Selective Laser Trabeculoplasty (SLT) application when used in the management of open angle glaucoma (OAG)
The purpose of this research is to determine the most effective method in using Selective Laser Trabeculoplasty (SLT) for lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. We will investigate the IOP lowering differences between nasal 180° SLT and inferior 180° SLT,. The second stage will assess the effect of repeating SLT in the opposite 180° sector after 3 months.
929 studies on the registry are indexed under Glaucoma, Open-Angle; 122 are open to participants now.
This study's enrollment of 13 is below the median of 80 across 700 interventional studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.
Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The Nasal 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. After 90 days, the Inferior 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye.
Procedure: Nasal 180° Selective Laser Trabeculoplasty (SLT) · Procedure: Inferior 180° Selective Laser Trabeculoplasty (SLT)
The Inferior 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. After 90 days, the Nasal 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye.
Procedure: Nasal 180° Selective Laser Trabeculoplasty (SLT) · Procedure: Inferior 180° Selective Laser Trabeculoplasty (SLT)
The Nasal 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. As per standard procedure, the laser will initially be set at 0.8 mJ (or 0.4 mJ for heavily pigmented TM). The energy level will then be adjusted in 0.1 mJ increments: increased until micro-bubble formation is observed or decreased if bubbles are noted. The desired endpoint is the production of a few fine 'champagne bubbles' every 2-3 laser spots. Larger gas bubbles and trabecular meshwork blanching will require the operator to titrate the power downwards in 0.1 mJ increments. Prophylactic IOP lowering and anti-inflammatory drops will be left to physician preference.
The Inferior 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. As per standard procedure, the laser will initially be set at 0.8 mJ (or 0.4 mJ for heavily pigmented TM). The energy level will then be adjusted in 0.1 mJ increments: increased until micro-bubble formation is observed or decreased if bubbles are noted. The desired endpoint is the production of a few fine 'champagne bubbles' every 2-3 laser spots. Larger gas bubbles and trabecular meshwork blanching will require the operator to titrate the power downwards in 0.1 mJ increments. Prophylactic IOP lowering and anti-inflammatory drops will be left to physician preference.
Difference in mean intraocular pressure (IOP)
During each visit, two consecutive IOP measurements will be obtained per eye, and the average of these values will be reported.
Time frame: Baseline, 3 months, 6 months, 9 months
Change in intraocular pressure (IOP)
Change in intraocular pressure (IOP), reported as a percentage
Time frame: Baseline, 3 months, 6 months, 9 months
Intraocular pressure (IOP) lowering eye drops
Total number of patients that did not need intraocular pressure (IOP) lowering drops after the selective laser trabeculoplasty (SLT)
Time frame: 9 months
Plan to share: No
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mayo Clinic